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Abstract
Systemic lupus erythematosus (SLE) is characterized by the production of a wide array of autoantibodies and dysregulation
of B cell function. The leukocyte associated Immunoglobulin (Ig)-like receptor (LAIR)1 is a transmembrane molecule
belonging to Ig superfamily which binds to different types of collagen. Herein, we have determined the expression and
function of LAIR1 on B lymphocyte from SLE patients. LAIR1 expression in peripheral blood B lymphocytes from 54 SLE, 24
mixed connective tissue disease (MCTD), 20 systemic sclerosis (SSc) patients, 14 rheumatoid arthritis (RA) and 40 sex and age
matched healthy donors (HD) have been analyzed by immunofluorescence. The effect of LAIR1 ligation by specific
monoclonal antibodies, collagen or collagen producing mesenchymal stromal cells from reactive lymph nodes or bone
marrow on Ig production by pokeweed mitogen and B cell receptor (BCR)-mediated NF-kB activation was assessed by ELISA
and TransAM assay. The percentage of CD20
+ B lymphocytes lacking or showing reduced expression of LAIR1 was markedly
increased in SLE and MCTD but not in SSc or RA patients compared to HD. The downregulation of LAIR1 expression was not
dependent on corticosteroid therapy. Interestingly, LAIR1 engagement by collagen or collagen-producing mesenchymal
stromal cells in SLE patients with low LAIR1 expression on B cells delivered a lower inhibiting signal on Ig production. In
addition, NF-kB p65 subunit activation upon BCR and LAIR1 co-engagement was less inhibited in SLE patients than in HD.
Our findings indicate defective LAIR1 expression and function in SLE B lymphocytes, possible contributing to an altered
control of B lymphocytes behavior.
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Introduction
The leukocyte associated Ig-like receptor (LAIR) 1 is a
transmembrane molecule belonging to the immunoglobulin (Ig)
superfamily expressed by all leukocytes [1–3]. Its cytoplasmic tail
contains immune receptor tyrosine-based inhibitory motifs (ITIM)
[1–3]. Upon engagement of the extracellular portion of LAIR1,
cytoplasmic ITIM bind to the SH2 domain of phosphatases,
leading to inactivation of different kinases and down-regulation of
cell activation. LAIR1 has been shown to inhibit T and NK cell
activation mediated by several activating receptors [4–7].
Furthermore, it has been shown that LAIR1 can deliver an
inhibiting signal on intracellular free calcium concentration and
immunoglobulin (Ig) production induced by the engagement of B
cell antigen receptors (BCR) [8,9]. Collagens are functional ligands
for LAIR1 and LAIR1-collagen interaction directly inhibits
immune cell activation [10–14]. Recently, we have reported that
the expression of LAIR1 on chronic B lymphocytic leukemia
(CLL) is inversely correlated with disease stage. More importantly,
BCR-mediated activation and proliferation of CLL cells was
inhibited upon LAIR1 engagement only in those patients
expressing LAIR1 at detectable levels [15]. Systemic lupus
erythematosus (SLE) is a immune-mediated chronic inflammatory
disease characterized by the presence of a wide variety of auto-
antibodies produced by dysregulated B cells [16–18]. The
initiating auto-antigen which is responsible for the disease is not
defined yet but it is relevant to determine whether B cells in SLE
patients may express a particular phenotype and a consequent
behaviour which may be the reason of the observed dysregulation.
The aim of this work was to analyze whether B cells of SLE
patients may lack LAIR1, thus impairing the interaction of B cells
with collagen, the known ligand of LAIR1, and missing an
inhibiting signal which regulates activating signals. For compar-
ison, LAIR1 expression was also determined on B lymphocytes
from patients suffering from mixed connective tissue disease
(MCTD), systemic sclerosis (SSc) and rheumatoid arthritis (RA).
We found that B cells from SLE and MCTD, but not RA or SSc,
patients are characterized by a lower LAIR1 expression,
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amount of B cells did not express LAIR1 at variance with B cells
from healthy donors where a very small subset was LAIR1. More
importantly, Ig production initiated through polyclonal mitogen B
cell stimulation was inhibited upon LAIR1 ligation by collagen, or
collagen-producing lymph node-derived mesenchymal stromal
cells (MSC), only in LAIR1
+ B cells. Likewise, BCR-induced NF-
kB p65 nuclear translocation was inhibited by LAIR1 engagement
only in B cells expressing high levels of the molecule. These
findings would suggest that Ig production in SLE patients may be
dysregulated, at least in part, because B cells do not express LAIR1
inhibiting receptor.
Materials and Methods
Ethics Statement
Patients suffering from systemic lupus erythematosus (SLE),
mixed connective tissue disease (MCTD), systemic sclerosis (SSc),
rheumatoid arthritis (RA) and healthy donors (HD) were enrolled
in the Vascular Endothelial Growth Factor Study approved by the
Ethic Committee of the San Martino Hospital (n.127/06). Bone
marrow specimens and lymph node biopsies were obtained during
diagnostic procedure to exclude lymphoproliferative diseases
(Ethic approval n.0026910/07). According to the ethic committee
approval, a written informed consent was obtained from all
participants.
Patients
Patients with SLE (n=50, table 1, and 4 patients with active
disease), MCTD (n=24), SSc (n=20) and RA (n=14) were
analyzed for the expression of LAIR1 on peripheral blood B
lymphocytes. Diagnoses were performed on the basis of ARA
(American Rheumatology Association) criteria for each disease.
Most patients (n=50) were analyzed for LAIR-1 expression and
function during a remission phase of the disease (no clinical
symptoms characteristic of the disease detectable); four patients
with active disease were also studied (SLEDAI.4). Forty aged and
sex matched HD were studied as controls. Venous blood samples
were drawn and immediately after isolation peripheral blood
mononuclear cells (PBMC) were analyzed for the expression of
LAIR1 on B cells, identified by the expression of CD20 and
surface IgM. Some samples were frozen and then analyzed in
functional experiments for Ig production and proliferation in
response to BCR engagement or upon stimulation with polyclonal
mitogen.
Monoclonal antibodies (mAbs) and reagents. Anti-
human LAIR1 (NKTA255, IgG1), and anti-CD3 (JT3A, IgG2a)
mAbs were obtained as described [19]. Anti-SH2 (CD105, IgG1),
anti-SH3 (CD73, IgG2b), mAbs producing hybridomas were
purchased from the American Type Culture Collection (ATCC,
Manassas, VA). Anti-HLAABC mAb (clone 3A3, IgM) mAb was
kindly provided by E. Ciccone (University of Genoa). Antiprolyl-4-
hydroxylase mAb (clone 5B5, IgG1) was purchased from Dako
(Glostrup, Denmark). Anti-human CD146 (clone P1H12, IgG1)
and unrelated isotype matched control mAbs were from BD
Pharmingen, anti-CD90 (clone Thy-1A1, IgG2a) and anti-
HMGB1 (clone 115603, IgG2b) mAbs were from R&D System
Inc. (Minneapolis, USA) and anti-CD27 mAb (clone LT27,
IgG2a) was from Serotec (Oxford, UK). Anti-BSP (bone
sialoprotein, clone LN-1, IgM) was from Abnova (Abnova
GmbH, Germany). Anti-ALP (alkaline phosphatase, clone 8B6,
IgG2a), anti-vimentin (clone V9, IgG1), anti-collagen I (clone
COL-1, IgG1) and anti-collagen III (clone FH-7A, IgG1) mAbs,
pokweed mitogen (PWM), acetoxymethyl-ester of fura 2 (Fura2-
AM), collagen I, II, III and goat anti-human m chain specific
FITC-conjugated polyclonal or purified monoclonal antibody
were from Sigma Chemicals Co. (St. Louis, MO, USA), while
macrophage-activating lipopeptide-2 (MALP2) was from Enzo
Life Sciences (Loerrach, Germany). Complete medium for culture
of PBMC or B cells was composed of RPMI1640 with 10% of fetal
calf serum supplemented with 1% antibiotics (penicillin and
streptomycin) and 1% L-glutamine (Biochrom, Berlin, Germany).
Isolation of peripheral blood mononuclear cells and B
cells. PBMC were isolated from venous blood samples by
separation on Ficoll-Hypaque as described previously [20]. In
some experiments, B lymphocytes from HD were selected by
negative selection. Briefly, purified B cells were obtained after
depletion of monocytes by plastic adherence and addition of red
blood cells to PBMCs at 30:1 ratio, with the RosetteSep B cell
enrichment kit (StemCell Technologies, Vancouver, Canada) and
were .98% pure as assessed by CD20 staining [20]. In some
experiments LAIR1
2 B cells (.95% LAIR1
2) from some SLE
patients were obtained from the whole B cell population after
negative selection using magnetic beads coated with GAM (Dynal,
Invitrogen srl).
Immunofluorecsence assay. PBMC samples from SLE,
MCTD or SSc patients and HD were stained with the indicated
mAbs followed by goat-anti-mouse isotype specific antibody
conjugated with the reported fluorochromes and then run on a
Cyan ADP cytofluorimeter (Beckman-Coulter) equipped with an
argon ion laser exciting FITC and PE at 488 nm or an He-Neon
far red laser exciting alexafluor647 isotype specific goat-anti
mouse (GAM). Results are expressed as log mean fluorescence
intensity (MFI) arbitrary units (a.u.) vs number of cells and
analyzed with the Summit v4.3 computer program (Beckman-
Coulter). Results of double or triple immunofluorescence assays
are expressed as log red MFI vs log green MFI or vs log far red
MFI. Samples for confocal microscopy were analyzed by FV500
(Fluoview confocal Laser Scanning Microscope System, Olympus
Europe GMBH, Hamburg, Germany) after observation with
PlanApo 406 NA1.00 or 606 NA1.40 oil objectives and data
analyzed with FluoView 4.3b computer program (Olympus).
Each image has been taken in sequence mode to avoid cross-
contribution of each fluorochrome. Results are shown in
pseudocolor.
Immunoglobulin (Ig) production assay
PBMC isolated from SLE or HD were incubated with PWM
(5 m g/ml) for 5 d at 37uC in complete medium. Then culture
supernatants (SNs) were harvested and analyzed for the presence
of human Ig of M, G and A isotype with a specific ELISA kit
purchased from Bethyl (Bethyl Laboratories Inc, Montgomery,
USA). The amount of Ig present in SNs was calculated with a
standard curve. To evaluate the inhibiting signal delivered by
LAIR1 on Ig production, parallel samples were preincubated with
anti-LAIR1 mAb for 30 min at 4uC, washed and incubated for 5 d
with PWM and goat anti-mouse immunoglobulin (GAM Ig) to
achieve LAIR1 oligomerization (LAIR1-XL). Other samples were
pretreated with an unrelated mAb matched for isotype as control.
In some experiments Ig production was evaluated in SN of PBMC
cultured for 5 d on plastic Petri dishes coated with a mixture of
collagen I, II and III (10 m g/ml) and with or without the F(ab9)2
fragment of anti-LAIR1 mAb prepared as described [21]. In
preliminary experiments, we determined that the use of F(ab9)2
does not induce appropriate engagement of LAIR1 for inducing
inhibiting signal but it was efficient in blocking ligation of LAIR1
with collagen.
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Patient Diagnosis age Sex
Year of
disease Therapy ESR ANA titer
CD20
+
LAIR1
2
pz1 DLE 51 F 16 MP 8 mg/die 28 1:80 35
pz2 SLE 51 F 27 MP 4 mg/die, Aza 100 mg/die 40 1:320 30
pz3 SLE 48 F 16 P 5 mg/die, My:2 g/die 37 1:160 46
pz4 SLE 43 F 16 P 2.5 mg/die ¸ My:1 g/die 12 1:160 14
pz6 SLE 36 F 8 P 5 mg/die, MTX:7.5 mg/w, HC:200 mg/die 8 1:160 23
pz7 SLE 38 F 10 MP 16 mg/die, My:2 g/die 24 1:640 18
pz10 SLE 71 F 22 P 5 mg/die, Aza:100 mg/die 58 1:80 47
pz11 SLE 45 F 6 P 12.5 mg/die; HC 200 mg/die, MTX 10 mg/w 14 1:160 25
pz12 SLE 36 M 2 P10 mg/die, Aza:100 mg/die, HC 200 mg/die 30 1:640 32
pz16 SLE 38 F 20 MP 40 mg/die, Aza 100 mg/die, CsA 150 g/die 5 1:80 24
pz17 SLE 67 F 31 MP 8 mg/die, Aza:100 mg/die, HC 200 mg/die 35 1:160 35
pz18 SLE+APS 36 F 4 MP 40 mg/die 30 1:160 26
pz19 SLE 68 M 19 MP 8 mg/die, CsA 100 mg/die 40 1:160 55
pz22 SLE 44 F 22 MP 4 mg/die 14 1:160 70
pz24 SLE 44 M 11 P 12.5 mg/die, Aza 100 mg/die 12 1:160 18
pz28 SLE 65 F 39 MP 4 mg/die 32 1:160 40
pz33 SLE 46 F 27 D 12 mg/die, Aza 50 mg/die 50 1:160 28
pz35 SLE 48 F 2 P 5 mg/die, My 1.5gr/die 34 1:160 28
pz42 DLE 46 F 3 F (topic) 18 1:320 29
pz44 SLE 27 F 3 MP 8 mg/die, My 2.0gr/die, HC 200 mg/die 17 1:320 22
pz47 SLE 22 F 1 P 2.5 mg/die, My 200 mg/die, 13 1:320 70
pz52 SLE 39 M 17 MP 16 mg/die 15 1:160 17
pz53 SLE 51 F 21 D 6 mg/die, My 1.5gr/die, HC 200 mg/die 10 1:160 61
pz54 SLE 57 F 24 MP 8 mg/die, My 1.0gr/die 16 1:160 11
pz55 SLE 35 F 15 MP 8 mg/die, HC:200 mg/die 30 1:160 31
pz59 SLE 65 F 15 MP 8 mg/die My 1.5gr/die, HC:200 mg/die 24 1.160 24
pz61 SLE 22 F 1 P 2.5 mg/die HC 200 mg/die 13 1:80 14
pz65 SLE 37 F 23 MP 4 mg/die 20 1:160 27
pz66 SLE 32 F 13 MP 8 mg/die, HC 200 mg/die 8 1:160 6
pz68 SLE 37 F 15 MP 40 mg/die, Cy 500 mg/die, CsA 200 mg/die 40 1:80 39
pz73 SLE 65 F 4 P 2.5 mg/die 16 1:80 20
pz76 SLE 31 M 7 D 6 mg/die, My 2gr/die, HC 200 mg/die 21 1:640 58
pz77 SLE 38 F 3 MP 8 mg/die, HC 200 mg/die 15 1:160 13
pz78 SLE 55 F 30 D 6 mg/die, HC:200 mg/die 20 1:80 36
pz80 SLE 36 F 18 P 5 mg/die, HC 200 mg/die, MTX 10 mg/w 8 1:160 66
pz81 SLE 39 F 18 P 5 mg/die, HC 200 mg/die, CsA 100 mg/die 11 1:640 50
pz82 SLE 45 F 19 MP 8 mg/die, HC 200 mg/die 28 1:160 45
pz14 SLE 34 F 12 HC 200 mg/die 18 1:160 16
pz20 SLE 49 F 18 none 20 1:160 60
pz37 SLE 65 F 25 MTX 7.5 mg/w 15 1:80 31
pz38 SLE 39 F 16 My 2gr/die 10 1:80 10
pz39 SLE 39 F 10 My 1gr/die 40 1:160 14
pz43 SLE 43 F 10 HC 200 mg/die 20 1:160 22
pz48 SLE+APS 63 F 1 MTX 7.5 mg/w 21 1:160 80
pz49 SLE 39 F 17 none 30 1:160 33
pz50 SLE+APS 47 F 10 none 8 1:80 18
pz51 SLE 63 F 13 none 5 1:160 18
pz56 SLE 44 F 16 HC 200 mg/die 16 1:160 3
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Human MSC were obtained as described [22] from 6 biopsies
of reactive lymph nodes (LMSC) isolated during diagnostic
procedure to exclude lymphoproliferative diseases. LMSC dis-
played a fibroblast-like morphology and expressed CD73, SH4,
CD105, CD44, b1-integrin/CD29, ICAM1/CD54, CD146,
HLA-I, prolyl-4-hydroxylase (the enzyme which catalizes the
hydroxylation of the aminoacid proline), alkaline phoshatase
(ALP), collagen, vimentin, bone sialoprotein BSP), and osteopontin
virtually on all cell populations analyzed. LMSC did not express
CD45, CD31, CD34, CD33, CD3, CD2, CD16, CD14, ICAM2,
ICAM3, CD80, CD86, CD83, and HLA-DR (not shown). The
surface phenotype of LMSC was stable along culture period (2–
3months, 25 doubling time). LMSC were co-cultured with
10
5PBMC or with purified B cells at the LMSC:PBMC/B ratio
of 1:4 in medium alone or in the presence of PWM in flat-
bottomed microplates in 200 m l and Ig content of supernatant was
analyzed as described above on day 5 of culture. This
LMSC:PBMC/B ratio was chosen because the inhibition of Ig
production was evident only at 1:2, 1:4 and 1:8 LMSC:PBMC/B
ratio as previously reported [23]. At 1:16 and 1:32 LMSC:PBMC/
B ratio we could not detect any inhibiting effect on Ig production
[24]. To determine the role of MSC-PBMC/B contact in
regulating B cell Ig production, in some experiments, PBMC
were seeded on Millicell transwell (TW) with 0.3 m m pores
(Millipore Corporation, Billerica, MA) put in 24-well plates with
LMSCs seeded on the bottom to avoid LMSC-PBMC/B cell
contact.
Calcium mobilization assay. Purified B cells were loaded
with fura-2AM (1 m M, Sigma) for 1 h at 37uC, placed in a quartz
2-ml cuvette and maintained at 37uC by a thermostatically
controlled water bath. Fura2-AM was exited at 334 and 380 nm,
emitted light was filtered at 510 nm and fluorescence was
monitored with an LS-50B spectrofluorimeter (Perkin-Elmer,
Pomona, CA). [Ca
2+]i, calculated as described [19], was
measured upon cross-linking of sIgM (IgM-XL), obtained with
the specific purified mAb followed by (GAM Ig), or after sIgM and
LAIR1 co-engagement (sIgM-LAIR1-XL).
NF-kB Transcription factor activation assay. NF-kB
activation was evaluated by the TransAM Assay Kit in nuclear
extracts obtained using the Nuclear Extract Kit (Active Motif,
Rixensart, Belgium) from B lymphocytes from HD or SLE patients
incubated for 12 h alone or after cross-linking of sIgM and/or LAIR1,
in the presence or absence of LAIR1pep or LAIR1mock. The SHP-
1-binding peptide, spanning the Tyr233-Tyr263 region of
LAIR1 cytoplasmic tail [15], VTYAQLDHWALTQRTARAVSP-
QSTKPMAESITYAAV (LAIR1pep), or the scrambled pep-
tide VAATDRWSYKPQETQALSHAYRMALTIVATSAQLVT
(LAIR1pepM) were obtained from PRIMM (Milan, Italy) and used
at the concentration of10 mg/ml,as reported [15].The time point was
chosen on the basis of preliminary kinetics experiments in order to
detect optimal NF-kB activation.T r a n s A MN F - k BK i t si sa9 6 - w e l l
plate with immobilized oligonucleotide containing the NF-kB
consensus site (59-GGGACTTTCC-39) that specifically binds to the
active form of NF-kB contained in cell extracts. Primary antibodies
directed against an epitope on p65 subunit, that is accessible only when
NF-kB is activated and bound to its DNA target, are then added,
followed by HRP-conjugated secondary antibody and reaction
developed by the specific substrate contained in the commercial kit.
Plates were then read with and ELISA reader and results expressed as
OD450 nm. Percent of activation of p65 NF-kB activation was
determined with the following formula: nucleus/total amount of p65
NF-kB 6100.
Statistical analysis
Statisticalanalysiswas performed using twotales Student’st testat
95% confidence or Pearson coefficient r with GraphPad Prism 4.0.
Results
SLE patients display higher percentage of CD20
+ B cells
lacking LAIR1 than healthy donors
First, we analyzed the expression of LAIR1 receptor on
peripheral B cells of SLE (n=50, table 1), AR (n=14), SSc
(n=20), or MCTD (n=24) patients and HD (n=40), by staining
PBMC with anti-LAIR1, anti-CD20 mAb followed by PE or
Alexafluor647-conjugated anti-isotype specific GAM and sIgM-
FITC conjugated antibodies. Results shown in figure 1A are gated
on sIgM
+ B cells. The percentage of CD20
+ B cells which did not
express LAIR1 was markedly increased in SLE patients compared
to HD (40610% vs 1065%, p,0.001) and to AR patients
(p,0.002) or SSc patients (p,0.002, fig. 1A left panel).
Furthermore, we found that the statistical significance of the
increase of CD20
+LAIR1
2 cells in SLE (p,0.001) patients treated
with corticosteroids was similar to that of untreated patients while
there was no a significant statistical difference between steroid
treated and untreated patients (p,0.198) (fig. 1A, right panel). In
addition, no correlation between the percentage of CD20
+LAIR1
2
B cells and cortisol equivalent dose administered to eachpatient was
found (r=20.185). Also, in MCTD patients an increment of
CD20
+LAIR1
2 B cells was detectable (p,0.001 vs HD, not shown)
and again no statistical differences were found between steroid
treated and untreated patients (p,0.309, not shown).
Some representative examples of the expression of LAIR1 on
unseparated PBMC from SLE, RA, or SSc patients and HD are
shown in fig. 1B. Of note, the MFI of LAIR1 on CD20
+LAIR1
+ B
cells was strongly decreased in SLE patients (MFI=3306120
arbitrary units, a.u.) as compared to HD (MFI=8156120a.u.).
Two groups among SLE patients on the basis of the pattern of
LAIR1 expression could be defined. The first group (SLE1, n=17)
Patient Diagnosis age Sex
Year of
disease Therapy ESR ANA titer
CD20
+
LAIR1
2
pz60 SLE 37 F 4 HC 200 mg/die 12 1:640 6
pz71 SLE 45 F 5 none 16 1:80 55
Diagnoses were based on ARA criteria. SLE: Systemic Lupus Erythematosus; APS: Anti-Phospholipid Syndrome; DLE: Discoid Lupus Erythematosus; ESR: Erythrocyte
Sedimentation Rate in mm/h (first hour); ANA: Anti-Nuclear Antibodies. nd: not done; CD20
+LAIR1
2 B cells determined by immunofluorescence in each patients are also
shown. MP: methyl-prednisolone; P: prednisone; D: deflazacort; F: fluocortolone; Aza: azathioprine; HC: hydroxy chloroquine; My: mycophenolate mofetil; CsA:
cyclosporin A; Cy: cyclophosphamide. Data of ESR, ANA and percentages of CD20
+LAIR1
2 cells are referred to the same sample of venous blood for each patient.
doi:10.1371/journal.pone.0031903.t001
Table 1. Cont.
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upper panels, first dot plot, CD20
+LAIR1
2 B cells .20%). The
second group, that includes the majority of SLE patients (SLE2,
n=43), displayed a lower MFI of LAIR1 expression and a higher
percentage of CD20
+LAIR1
2 B cells than HD (fig. 1B, upper
panels, second dot plot vs lower panels first dot plot,
CD20
+LAIR1
2B cells 60610% vs 1065%, p,0.001) or AR
patients (fig. 1B, lower panels, second dot plot). Finally, LAIR1
expression on B cells in SLE patients with active disease has been
analyzed in 4 cases (one shown in fig. 1B, upper panels, third dot
plot): in these cases MFI was superimposable to that of SLE in
remission phase (MFI=3006100 a.u. vs 3306120 a.u.) while the
percentage of CD20
+LAIR1
2 cells was 30610%.
We analyzed whether the lower expression of LAIR1 on B cells
of SLE patients was related to an imbalance between naive and
memory B cells. Thus, we labeled HD, SLE and MCTD PBMC
with anti-CD27, anti-LAIR1 and anti-CD20 mAb to identify
CD20
+CD27
2 as naı ¨ve or CD20
+CD27
+ as memory B cells
respectively. We found that LAIR1 was expressed by most if not
all CD20
+CD27
2 naı ¨ve B cells in any kind of patients or HD;
likewise, more than 70% of CD20
+CD27
+ memory B cells were
LAIR1
+ in SLE, MCTD, SSc and HD, suggesting no evident
imbalance of naı ¨ve and memory B cell subsets in patients analyzed
(fig. 2A) The decreased expression of LAIR1 in SLE and MCTD
patients may be related to the activation of B cells as previously
reported (8). Thus, we analyzed whether LAIR1 expression was
effectively down-regulated during activation of B cells. To this aim,
highly purified (.95% CD20
+) healthy B cells were cultured with
different polyclonal B cell stimuli as anti-IgM antibodies (anti-
BCR), or PWM or MALP2 by adding IL2 on d2 and LAIR1
expression was evaluated on d6 of culture. PWM or MALP2 were
used to mimic B cell stimulation through other receptor than
BCR. The effective activation of peripheral B cells was assessed by
the increase of expression of CD38 and neo-expression of CD25
antigens (not shown). A statistically significant reduction of
fluorescence intensity of LAIR1 expression (p,0.001) was found
on d6 after B cell stimulation through BCR compared to ex-vivo B
cells (MFI=8156120a.u. on d0 vs MFI=650690a.u. after anti-
BCR stimulation, fig. 2B). Stimulating B cells with PWM or
MALP2 (fig. 2B), a slightly reduction of LAIR1 expression was
detected. It is of note that the percentage of CD20
+LAIR1
2 B cells
found in a given donor was not increased by any of the stimuli
Figure 1. Expression of LAIR1 on PBMC from SLE or RA or SSc patients and HD. A. Peripheral blood mononuclear cells (PBMC) were isolated
from SLE (n=50) or RA (n=14) or SSc (n=20) patients and stained with anti-LAIR1 mAb and anti-CD20 mAb followed by goat anti-isotype specific
GAM conjugated with either PE or Alexafluor647 and goat anti-human sIgM-FITC polyclonal antibody. Results are expressed as CD20
+LAIR1
2 B cells
gated on sIgM
+ cells. Surface IgM
+ B cells were 95–100% of all B cells in PBMC of any population tested. The percentages of CD20
+LAIR1
2 cells
present in PBMC of healthy donors (HD) is shown for comparison in each panel (n=40). A, right panel: Patients suffering from SLE were subdivided in
two groups (with or without steroid therapy). The statistical significance of results is shown in each panel. B. Some representative examples of
expression of CD20 and LAIR1 on PBMC of SLE in remission phase (SLE1 and SLE2) or in acute phase (SLE flare) or RA or SSc patients and HD. Results
are expressed as Log far red fluorescence intensity vs Log red fluorescence intensity. Each dot plot is subdivided into four quadrants representing
CD20
2LAIR1
+ (upper left) or CD20
+LAIR1
+ (upper right) or CD20
2LAIR1
2 (lower left) or CD20
+LAIR1
2 (lower right) cells respectively.
doi:10.1371/journal.pone.0031903.g001
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clarify whether, besides B cells, also T lymphocytes showed a
decreased LAIR1 expression in SLE patients. We found that
LAIR1 was expressed on T lymphocytes of SLE and MCTD
patients at levels comparable to those detected on T cells from HD
and SSc patients (not shown); in addition, the percentages of
LAIR1
+ and LAIR1
2 T cells present in peripheral blood were
similar in SLE, MCTD, SSc and HD (fig. 2C).
LAIR1 oligomerization induces the down-regulation of Ig
production on healthy B lymphocytes: this effect is
related to LAIR1 expression in SLE patients
We then analyzed whether the ligation of LAIR1 could affect Ig
production in SLE patients and whether this effect was related to
the level of LAIR1 antigen expression on B cells. To this aim,
PBMC isolated from SLE patients were stimulated for 5 d with the
polyclonal stimulus PWM and SNs were collected and analyzed
for the presence of human Ig by ELISA. Parallel samples of
PBMC from HD were stimulated with PWM as control. Healthy B
cells produced Ig upon stimulation with PWM (fig. 3A, left panel)
and LAIR1 oligomerization strongly inhibited Ig production
(fig. 3A, right panel). Indeed, IgM or IgG or IgA release in culture
SN was reduced by 50–60% or 60–70% or 80–90% respectively
by the engagement of LAIR1. Upon stimulation with PWM,
PBMC from SLE patients produced amounts of IgM, IgG and IgA
at similar levels as PBMC from HD (fig. 3A, left). Of note,
inhibition of PWM-induced Ig production following LAIR1
engagement in PBMC of SLE patients with B cells expressing
low levels of LAIR1 or high fraction of LAIR1
2 (SLE2 group) was
markedly reduced compared to that found in healthy PBMC.
Indeed, Ig production in SLE2 group was 85% of that found
without LAIR1 engagement (fig. 3A) with a statistically significant
difference between SLE2 and HD (p,0.01, fig. 3A, right panel).
On the other hand, LAIR1-mediated inhibition of Ig production
by SLE B cells expressing normal LAIR1 levels (SLE1 group) was
comparable to that found in HD. Finally, a strong direct
correlation between the % of LAIR1
+ B cells and the % of
LAIR1-mediated inhibition on PWM-induced Ig production was
found (r=0.94 or r=0.91 or r=0.87 for IgM or IgG or IgA
respectively).
LAIR1-collagen interaction do not inhibit Ig production in
SLE patients expressing low levels of LAIR1 or with a
large proportion of LAIR1
2CD20
+ B cells
It is relevant to analyze the effects of engagement of LAIR1 in
SLE patients upon interaction with its natural ligand that is
collagen [10–13]. Thus, in a first series of experiments, we
analyzed whether the lack or low expression of LAIR1 on B cells
of SLE patients could lead to a decrease of the inhibiting signal
delivered to B cells upon LAIR1-collagen interaction. In order to
test the LAIR1-mediated inhibiting signal, we evaluated Ig
production by PWM stimulated B cells; we chose this kind of
stimulation as it was polyclonal and not necessarily dependent on
interaction with BCR. We found that the production of Ig was
reduced by culturing healthy B cells on collagen-coated plates.
Indeed, IgM or IgG or IgA production on collagen was about 50%
or 30% or 40% respectively of that in absence of collagen (fig. 3B,
left panel). This inhibiting effect was partially reverted (about 50%
Figure 2. Expression of LAIR1 on naı ¨ve and memory B cells, effect of B cell activation on LAIR1 expression and LAIR-1 expression on
T cells. Panel A. Percentage of LAIR1
+ (black bar) or LAIR1
2 B (grey bar) cells in naı ¨ve (CD27
2) or memory (CD27
+) cell subsets. Results are
determined by triple immunofluorescence assay using specific mAbs to CD20, LAIR1 and CD27 followed by isotype specific GAM conjugated with
Alexafluor674 (CD20) or PE (LAIR1) or Alexafluor488 (CD27) on HD or SLE or MCTD or SSc patients. Panel B. Effect of B cell activation on LAIR1
expression. Highly purified healthy B cells were stimulated with sIgM or PWM or MALP2, as indicated, and expression of LAIR1 and CD20 was analyzed
as in A. Results are representative of seven independent experiments. Panel C. Expression of LAIR1 on T cells from healthy donors (HD), SLE, MCTD
and SSc patients. PBMC were stained with anti-CD3 (JT3A, IgG2a) and anti-LAIR1 (IgG1) mAb followed by anti-isotype specific GAM conjugated with
Alexafluor647 or PE respectively. Results are expressed as percentages of CD3
+ LAIR1
+ (dark grey bar) or CD3
+LAIR1
2 (light grey bar) T cells.
doi:10.1371/journal.pone.0031903.g002
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fragment of LAIR1 mAb. No effect was exerted by an isotype
matched unrelated mAb (fig. 3B).
As shown in Fig. 3B (right panel), the collagen-LAIR-1-
mediated inhibition of Ig production was almost not detected
(about 10% of inhibition) in SLE2 patients which express low
levels of LAIR1 and a large proportion of LAIR1
2CD20
+ B cells.
Indeed, the production of IgM, IgG and IgA was similar to that
observed in the absence of collagen (e.g for IgM: 410615 ng/ml
in PBMC vs 350625 ng/ml in PBMC cultured on collagen).
Importantly, the production of IgM. IgG and IgA in the presence
of collagen in SLE2 patients was statistically significant increased
compared to that found in HD under the same culture conditions
(p,0.01).
The interaction of B cells with collagen-producing MSC
inhibits Ig production through the involvement of LAIR1
in HD: this effect is defective in SLE B cells
We also determined whether collagen producing cells can
deliver an inhibitory signal on Ig production through LAIR1
engagement. Indeed, it is commonly accepted that the production
of Ig can happen in lymph nodes and in SLE disease the
interaction between lymph node-derived mesenchymal stromal
cells (LMSC) and B cells can be considered as a pathophysiological
conditions where the lack of expression of LAIR1 can contribute
to altered Ig production because the interaction of LAIR1 and
collagen produced by LMSC is impaired. To this aim, we first
established appropriate culture conditions to expand in vitro
LMSC from lymph nodes, then we determined whether they can
produce collagen and finally LMSC were cultured with healthy B
cells or B cells from SLE patients, stimulated with PWM and SNs
were analyzed for Ig content on d5. The surface and cytoplasmic
phenotype of LMSC used in these experiments is shown in
figure 4A. LMSC were typical fibroblast-like cells expressing
surface markers of mesenchymal stromal cells as CD73, CD90,
CD105 and CD146 (fig. 4A) but lacking markers characteristic of
leukocyte including CD34, CD33, CD80, CD86 and HLA-DR
(not shown). Importantly, LMSC expressed cytoplasmic alkaline
phosphatase, bone sialoprotein, vimentin and collagen as shown
by immunofluorescence and FACS analysis (fig. 4A) on permea-
bilized LMSC and could release collagen in the extracellular
microenvironment as shown by immunofluorescence and confocal
microscopy analysis (fig. 4B). Indeed, collagen outside of cells
Figure 3. Production of Ig by PBMC from SLE patients stimulated with pokeweed mitogen: regulation through the engagement of
LAIR1 and collagen. A. Immunoglobulin production of the indicated isotype (A or G or M) from healthy donors (HD) or SLE patients was analyzed
with specific ELISA kit in cell culture supernatant after stimulation for 5 d of PBMC with pokeweed mitogen alone (PWM) (left) and upon cross-linking
of LAIR1 (PWM LAIR1-XL) (right). Results are expressed as ng/ml/10
5 CD20
+ B cells. Ig production of PBMC from HD (n=25) is shown for comparison.
In the right panel the statistical significance was shown between HD+PWM and HD+PWM-LAIR1-XL, or HD and SLE2 or SLE1 groups in PWM-LAIR1-XL
culture condition. Panel B. PBMC of HD, (n=8, left) or SLE patients (n=10 from SLE2 group, right) were incubated for 5 d on collagen coated plates.
Then SN were analyzed for the presence of the human IgM, IgG and IgA by ELISA. In some experiments, F(ab9)2 of anti-LAIR1 mAb (5 m g/ml) to
compete with the interaction of surface LAIR1 and collagen or an unrelated mAb matched for the isotype as control mAb (5 m g/ml) was added at the
onset of cell culture. Results are expressed as ng/ml/10
5 CD20
+ B cells as mean6SD. * p,0.001 vs basal production of Ig. **p,0.001 vs Ig production
of PBMC on collagen coated plates. In the right panel is indicated the statistical significance of Ig production in the culture condition PBMC+collagen
in SLE2 patients vs HD.
doi:10.1371/journal.pone.0031903.g003
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(fig. 4B, left). In addition, LMSC expressed into the cytoplasm
prolyl-4-hydroxylase (fig. 4B, right), the enzyme involved in the
hydroxylation of collagen. All these features strongly support that
LMSC can be considered as cells able to synthetize, process and
secrete collagen in the extracellular milieu where it can interact
with LAIR1 expressed on B cell surface and deliver an efficient
inhibiting signal. Indeed, SN harvested from co-cultures of healthy
B cells stimulated with PWM in the presence of LMSC contained
a lower amount of Ig than that found in B cell cultured alone; the
optimal LMSC:B cell ratio at which an evident reduction of Ig
production was detected was the 1:4 LMSC:B cell ratio (fig. 4C)
(30% or 40% or 50% of IgM or IgG or IgA of the amount
produced without LMSC). Although not shown, this inhibiting
effect was evident only when B cells were in contact with LMSC;
indeed, no inhibition of Ig production was detected when B cells
were co-cultured with LMSC separated by a transwell Millicell
chamber. Importantly, the addition of the F(ab9)2 fragment of anti-
LAIR1 mAb, thus conceivably impairing LAIR1-collagen inter-
action, partially restored Ig production when B cells were in
contact with LMSC (fig. 4C) (90% or 95% or 98% of IgM or IgG
or IgA of the amount produced without LMSC), suggesting that,
also in this experimental system, LAIR1 surface molecule
interacting with collagen can deliver an inhibiting signal on B
cells. On the other hand, the Ig production in the SLE2 group of
patients in the presence of LMSC was really stronger than that of
healthy B cells (270 ng/ml vs 130 ng/ml in SLE2 vs HD). Indeed,
in SLE2 group, the amount of IgM or IgG or IgA produced with
MSC was 70% or 71% or 80% of that produced without LMSC
respectively. The addition of anti-LAIR1 mAb did not lead to a
statistically significant increment of Ig production, suggesting that
LAIR1 inhibiting signal is not operating in SLE2 patients.
LAIR1-induced regulation of BCR-mediated calcium
mobilization and nuclear translocation of NF-kB p65
subunit is defective in B cells from SLE patients
We next analyzed whether LAIR1 engagement interferes with
early BCR-mediated signaling events, such as calcium mobiliza-
tion and NF-kB nuclear translocation. First, we found that LAIR1
engagement could reduce BCR-induced calcium mobilization
obtained upon sIgM cross-linking in B lymphocytes from HD
(fig. 5A, upper panel and fig. 5B); this inhibition was defective in
SLE patients (fig. 5A central panel and fig. 5B) and absent in
LAIR1 negative B cells fractionated from SLE2 patients (fig. 5A
lower panel and fig. 5B). Furthermore, the NF-kB subunit
translocation induced through BCR engagement is less inhibited
in SLE2 patients which express low levels of LAIR1. The p65 NF-
kB subunit activation (i.e. its nuclear translocation) was evaluated
Figure 4. Collagen-producing LMSC regulate Ig production upon engagement of LAIR1: this effect is defective in SLE patients. A,
LMSC from a representative reactive lymph node were surface stained with the indicated mAbs (first row) followed by PE-conjugated anti-isotype
specific goat anti-mouse antiserum. Control: cells stained with an unrelated mAb followed by GAM as negative control. Second row: LMSC were
cytoplasmic stained after fixation and permeabilization with mAbs to the indicated molecules (ALP: alkaline phosphatase, BSP: bone sialoprotein,
collagen or vimentin) followed by PE-conjugated GAM. Results are expressed as log red fluorescence intensity vs number of cells. In each panel are
indicated the percentages of positive cells above the horizontal bar set on negative control (first subpanel on the left of each row). B. left: bright field
(BF) of LMSC from a representative reactive lymph node (upper left), staining with anti-collagen mAb (upper right, red) without cell permeabilization
and the respective negative controls (BF neg control, neg control). B right: staining of LMSC with anti-HLA-I (surface, green), anti-prolyl-4-hydroxylase
(P4H, cytoplasmic, red) and anti-HMGB1 mAb (nucleus, blue) analyzed by confocal microscopy. Merge analysis is also shown. 4006(left), 6006(right)
magnification. White Bars: 10 m m; reactivity for collagen is disposed in large and concentrated regions (upper left); the white arrows indicate the
intracytoplasmic reactivity for P4H (upper right). C. PBMC of healthy donors (HD, n=7, left) or SLE patients (n=9 from SLE2 group, right) were
incubated for 5 d on collagen-producing mesenchymal stromal cells (MSC) from reactive lymph node coated plates. Then SN were analyzed for the
presence of the human IgM, IgG and IgA by ELISA. In some experiments, F(ab9)2 of anti-LAIR1 mAb (5 m g/ml) to compete with the interaction of
surface LAIR1 and collagen-producing MSC or an unrelated mAb matched for the isotype as control mAb (5 m g/ml) was added at the onset of cell
culture. Results are expressed as ng/ml/10
5 CD20
+ B cells as mean6SD. * p,0.001 vs basal production of Ig. ** p,0.001 vs Ig production on LMSC
coated plates. In the right panel is indicated the statistical significance of Ig production in the culture condition PBMC+LMSC in SLE2 patients vs HD.
doi:10.1371/journal.pone.0031903.g004
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from SLE patients (n=5) whole B cell population (i.e.
CD20
+LAIR1
+ and CD20
+LAIR1
2) before or after cross-linking
of BCR alone or with LAIR1 engagement (fig. 5C). A strong p65
nuclear translocation was induced upon sIgM engagement in HD
similar to that observed in SLE patients (from basal level of 10–
15% to 65–80%) In B cells of HD, LAIR1 oligomerization was
able to inhibit the p65 subunit NF-kB activation induced via sIgM
engagement from 65% to 35%. On the other hand, LAIR1
engagement inhibits at a lower extent BCR-induced NF-kB
activation on B cells of SLE patients compared to HD (degree of
p65 activation in HD 35% vs 55% in SLE, p,0.01). Finally, we
isolated CD20
+LAIR1
2 B cells from SLE patients and we found
that BCR mediated p65 subunit NF-kB activation was not
inhibited by LAIR1 engagement (fig. 5C). Importantly, pre-
incubation of B cells with the SHP-1-binding peptide of ITIM
domain of LAIR1 abrogated the inhibiting effect mediated
through LAIR1 engagement in HD and SLE patients, whereas
the scrambled peptide, used as a control, did not affect the LAIR1-
mediated inhibiting signal (fig. 5C). These peptides did not affect
the response of CD20
+LAIR1
2 B cells of SLE patients.
Discussion
Herein, we have shown that in patients suffering from SLE the
inhibiting surface receptor LAIR1 is expressed on a smaller
fraction of CD20
+ B cells than in healthy donors. This decrease in
CD20
+LAIR1
+ B cells is not related to corticosteroid treatment
and it appears as a characteristic feature of SLE but not of RA or
SSc. Two groups of SLE patients were identified on the basis of
the amount of CD20
+LAIR1
2 B cells and the level of expression
of LAIR1 on CD20
+LAIR1
+ B cells. Indeed, the SLE1 subgroup
Figure 5. Regulation of BCR-induced calcium mobilization and activation of p65 NF-kB subunit by co-engagement of LAIR1 is
defective in SLE patients. A and B. Purified B cells obtained from HD (n=4) or SLE2 (n=4), as indicated, were loaded with fura-2AM (1 m M), and
[Ca
2+]i increase was analyzed by monitoring fluorescence with an LS-50B spectrofluorimeter. In some experiments LAIR1
2 B( .95%) cells from SLE2
patients were obtained from the whole B cell population after negative selection using magnetic beads coated with GAM. [Ca
2+]i, was measured
upon cross-linking of sIgM (IgM-XL), obtained with the specific purified mAb followed by (GAM Ig), or upon co-engagement of sIgM and LAIR1 (sIgM-
LAIR1-XL), as indicated. B. D [Ca
2+]i, mean6SD from 4HD or 4 SLE2 (unfractionated B cells or LAIR1
2 B cells. C. B cells were separated from either HD
(n=6) or SLE patients (n=5) or CD20
+LAIR1
2 cells from SLE (n=3) alone or stimulated through BCR (with sIgM antibody, 5 m g/ml) for 12 h and then
nuclear lysates were analyzed for the activation of NF-kB subunit p65. Activation of p65 was determined by evaluating the % of p65 present in
nucleus extracts and total p65 protein for each sample. In some experiments, cells were pre-incubated for 30 min in the presence or absence of the
SHP-1- binding peptide (pep) or the scrambled peptide (pep-mock) and cross-linking of LAIR1 (LAIR1mAb-XL). * p,0.001 vs activation of p65 NF-kB
upon sIgM engagement (BCR-mediated stimulation). The statistical significance between the p65 activation in HD and SLE patients upon different
culture condition is shown in the panel.
doi:10.1371/journal.pone.0031903.g005
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group, that includes the majority of SLE patients, showed a low
level of LAIR1 expression and a high fraction of CD20
+LAIR1
2 B
cells. The inhibiting signal delivered through the engagement of
LAIR1 by collagen or collagen-producing cells is not fully
functional in B cells in SLE2 patients suggesting that in these
patients the B cells Ig-producing capacity cannot be adequately
regulated by the interaction of LAIR1 with collagen or with
collagen-producing LMSC. This suggests that in SLE the defective
LAIR1 expression on B cells may leave these cells to be fully
stimulated by still undefined polyclonal stimuli and/or auto-
antigens and, then, to proliferate and produce potentially
pathogenic Ig, without the negative regulation initiated upon
collagen-LAIR1 interaction. Interestingly, we found that LAIR1 in
a subgroup of SLE patients was expressed on B cells at similar level
than in healthy donors. Indeed, the engagement of LAIR1 in these
patients led to a reduced synthesis of different Ig isotypes similarly
to what observed in healthy B cells. On the other hand, the lower
expression or the lack of LAIR1 in the other subgroup of SLE
patients resulted in the strong reduction of LAIR1-mediated Ig
synthesis inhibition. These findings would suggest that LAIR1 can
mediate an inhibiting signal only when expressed as in healthy B
cells and there is a threshold for giving the inhibiting signal as well.
A possible limitation of our study is that we did not analyze the
expression of LAIR1 on B cells during the acute phase of the SLE
disease in a high number of patients and after therapy. Indeed, all
our patients were recruited in a remission phase of the disease in
the absence of evident symptoms. SLE is a pleiotropic disease that
may hit several organs and the clinical manifestation are quite
variegated [25–29]. Each patient may respond to a complex
therapy with different immunosuppressant in a characteristic
manner [26–30]. We choose patients mostly with no evident
disease activity because we try to find a difference in LAIR1
expression and function between healthy individuals and SLE
affected patients, avoiding the contribution of other elements due
to the flare of the illness and therapy. Nevertheless, we analyzed a
limited number of patients with active disease and found a reduced
expression of LAIR1 on B cells, compared with HD, without an
evident increase in the percentage of CD20
+LAIR1
2 cells.
We have recently reported that LAIR1 is downregulated in B
cells of chronic lymphocytic leukaemia (CLL) [15]. Interestingly,
in CLL the engagement of LAIR1 with specific mAbs blocks the
constitutive and BCR-mediated Akt phosphorylation and NF-kB
nuclear translocation, leading to inhibition of B cell proliferation.
Importantly, this inhibiting effect was not evident in LAIR1
2 CLL
cells [15]. In this report, we show that the oligomerization of
LAIR1 on whole peripheral blood B cell population, but not in
LAIR1
2 B cells, can affect BCR-mediated calcium mobilization,
in keeping with a previous report [8], and NF-kB p65 nuclear
translocation. It is known that BCR induced calcium mobilitation,
and the following activation cascade, is dysregulated in B cells
from SLE patients [30]; one possible regulating mechanism
missing in SLE B lymphocytes might be related to the lower or
absent expression of LAIR1 and of its ITIM domain. Another
ITIM-dependent dysregulation of BCR-induced B cell activation
in SLE patients might be related to a deficient FccIIbR mediated
suppression; indeed, dysfunction of this low affinity Ab receptor,
which is equipped with a cytoplasmic ITIM like LAIR1, is
associated with autoimmunity and it has been described in SLE
patients [31]. Taken together these findings, we would suggest that
the inhibition of activation of NF-kB is a key point of the LAIR1-
mediated regulation of B cell response. In addition, Akt and NF-
kB are targets for the action of LAIR1 also in primary myeloid
leukemias [32,33] indicating that anywhere LAIR1 is expressed, its
engagement evokes a similar cellular response. We have found that
LAIR1 is expressed on the majority of naı ¨ve and memory B cells.
The discrepancy of this result with the reported down-regulation
of LAIR1 on memory and activated B cells [8] may be dependent
on the different anti-LAIR1 mAb used in these studies. In
addition, we cannot exclude that our anti-LAIR1 mAb can
recognize the different isoforms of LAIR1 that can be expressed on
lymphocytes [2]. It is conceivable that in SLE patients would be
present the auto-antigen(s) which is responsible for the disease,
thus the observed downregulation of LAIR1 found in SLE patients
and the strong increment in CD20
+LAIR1
2 B cell fraction in a
subgroup of patients would be linked to an in vivo downregulation
of LAIR1 upon B cell activation. In this context, we detected a
statistically significant downregulation of LAIR1 upon stimulation
of healthy B cells with BCR, but this downregulation was not so
evident stimulating B cells with polyclonal mitogens. In addition,
we did not detect a shift from LAIR1
+ to LAIR1
2 B cells upon in
vitro stimulation. This finding would suggest that the lack of
LAIR1 on a fraction of SLE B cells is not strictly linked to in vivo
activation. Also steroid therapy may have a role in downregulating
LAIR1 expression. Indeed, the large majority of SLE patients were
under steroid therapy (table 1), however, we found a strong
heterogeneity of LAIR1 expression among SLE patients treated
with steroids and there was no correlation between steroid therapy
and LAIR1 expression. In addition, we found that the percentage
of CD20
+LAIR1
2 B cells were different from those found in
healthy donors also in steroid untreated patients. This would
suggest that steroid do not play a key role in the observed
downregulation of LAIR1 antigen on SLE B cells.
Recently, it has been reported that LAIR1 expression is lower
on plasmacitoid dendritic cells (PDC) in SLE pediatric patients
compared to that found in healthy donors [34]. This would
indicate that the downregulation of LAIR1 in SLE patients can
affect cell populations which play a key role in regulating immune
response. In this context, it would be of interest to analyze whether
PDC can further increment B cell response and whether the lower
expression of LAIR1 on both PDC and B cells can result in a lower
inhibiting signal mediated through LAIR1 and collagen-producing
MSC in lymph node and/or bone marrow. In conclusion, this
work points out the relevance of the lack of LAIR1-mediated
inhibiting signal upon interaction with collagen produced in the
microenvironment by stromal cells as a trigger for the dysregu-
lation of antibody production in SLE patients.
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